Reproductive and obesity medicine experts tell USA TODAY that they’re also noticing the trend in their offices, and it boils down to two main reasons.  Weight loss can help correct ...

The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

Rybelsus, the oral form of Semaglutide launched by Novo Nordisk in January 2022, has grown from Rs 26 crore to Rs 412 crore, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...